CVAD regimen: Difference between revisions
No edit summary |
No edit summary |
||
(One intermediate revision by the same user not shown) | |||
Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AV}} | {{CMG}}; {{AE}} {{AV}} | ||
{{SK}}CHOD; CTX/DM/DOX/VCR; CVAD; Cyclophosphamide/Dexamethasone/Doxorubicin/Vincristine | {{SK}} CHOD; CTX/DM/DOX/VCR; CVAD; Cyclophosphamide/Dexamethasone/Doxorubicin/Vincristine | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a regimen consisting of [[cyclophosphamide]], [[vincristine]], [[Doxorubicin|adriamycin (Doxorubicin)]], [[dexamethasone]] used to treat Multiple myeloma.<ref name="pmid22058209">{{cite journal| author=Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N et al.| title=Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. | journal=Haematologica | year= 2012 | volume= 97 | issue= 3 | pages= 442-50 | pmid=22058209 | doi=10.3324/haematol.2011.043372 | pmc=PMC3291601 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22058209 }} </ref> | {{PAGENAME}} refers to a regimen consisting of [[cyclophosphamide]], [[vincristine]], [[Doxorubicin|adriamycin (Doxorubicin)]], [[dexamethasone]] used to treat Multiple myeloma.<ref name="pmid22058209">{{cite journal| author=Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N et al.| title=Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. | journal=Haematologica | year= 2012 | volume= 97 | issue= 3 | pages= 442-50 | pmid=22058209 | doi=10.3324/haematol.2011.043372 | pmc=PMC3291601 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22058209 }} </ref> | ||
==Regimen== | ==Regimen== | ||
Line 15: | Line 13: | ||
{{chemo|C|Cyclophosphamide}} | {{chemo|C|Cyclophosphamide}} | ||
{{chemo|V|Vincristine}} | {{chemo|V|Vincristine (Oncovin)}} | ||
{{chemo|A|Doxorubicin (Adriamycin)}} | {{chemo|A|Doxorubicin (Adriamycin, Hydroxydaunorubicin)}} | ||
{{chemo|D|Dexamethasone}} | {{chemo|D|Dexamethasone}} | ||
Line 29: | Line 27: | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Chemotherapy regimens]] |
Latest revision as of 18:14, 17 March 2015
WikiDoc Resources for CVAD regimen |
Articles |
---|
Most recent articles on CVAD regimen Most cited articles on CVAD regimen |
Media |
Powerpoint slides on CVAD regimen |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on CVAD regimen at Clinical Trials.gov Clinical Trials on CVAD regimen at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on CVAD regimen
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on CVAD regimen Discussion groups on CVAD regimen Patient Handouts on CVAD regimen Directions to Hospitals Treating CVAD regimen Risk calculators and risk factors for CVAD regimen
|
Healthcare Provider Resources |
Causes & Risk Factors for CVAD regimen |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: CHOD; CTX/DM/DOX/VCR; CVAD; Cyclophosphamide/Dexamethasone/Doxorubicin/Vincristine
Overview
CVAD regimen refers to a regimen consisting of cyclophosphamide, vincristine, adriamycin (Doxorubicin), dexamethasone used to treat Multiple myeloma.[1]
Regimen
CCyclophosphamide
VVincristine (Oncovin)
ADoxorubicin (Adriamycin, Hydroxydaunorubicin)
DDexamethasone
Indications
References
- ↑ 1.0 1.1 Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N; et al. (2012). "Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results". Haematologica. 97 (3): 442–50. doi:10.3324/haematol.2011.043372. PMC 3291601. PMID 22058209.